AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
44.41
+1.11 (2.56%)
At close: Dec 5, 2025, 4:00 PM EST
44.35
-0.06 (-0.14%)
After-hours: Dec 5, 2025, 5:01 PM EST
AnaptysBio Revenue
AnaptysBio had revenue of $76.32M in the quarter ending September 30, 2025, with 154.26% growth. This brings the company's revenue in the last twelve months to $169.47M, up 196.42% year-over-year. In the year 2024, AnaptysBio had annual revenue of $91.28M with 432.03% growth.
Revenue (ttm)
$169.47M
Revenue Growth
+196.42%
P/S Ratio
7.70
Revenue / Employee
$1,246,081
Employees
136
Market Cap
1.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 91.28M | 74.12M | 432.03% |
| Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
| Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
| Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
| Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
| Dec 31, 2019 | 8.00M | 3.00M | 60.00% |
| Dec 31, 2018 | 5.00M | -5.00M | -50.00% |
| Dec 31, 2017 | 10.00M | -6.68M | -40.06% |
| Dec 31, 2016 | 16.68M | -887.00K | -5.05% |
| Dec 31, 2015 | 17.57M | 1.73M | 10.94% |
| Dec 31, 2014 | 15.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ANAB News
- 11 days ago - Anaptys Announces Participation in December Investor Conferences - GlobeNewsWire
- 15 days ago - AnaptysBio shares tumble after legal fight with GSK over cancer drug license - Reuters
- 15 days ago - GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties - Benzinga
- 15 days ago - GSK, AnaptysBio Sue Each Other Over Cancer Drug License - WSJ
- 15 days ago - Anaptys Announces $100 Million Stock Repurchase Plan - GlobeNewsWire
- 15 days ago - Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary - GlobeNewsWire
- 23 days ago - AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement - Seeking Alpha
- 26 days ago - AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study - Benzinga